Elsevier

Pathology

Volume 37, Issue 6, December 2005, Pages 534-550
Pathology

Vaccine strategies to treat lymphoproliferative disorders

https://doi.org/10.1080/00313020500376462Get rights and content

Summary

Lymphoproliferative disorders, including follicular lymphoma (FL), multiple myeloma (MM) and chronic lymphatic leukaemia (CLL), are slowly progressive malignancies which remain incurable despite advances in therapy. Harnessing the immune system to recognise and destroy tumours is a promising new approach to treating these diseases. Dendritic cells (DC) are unique antigen-presenting cells that play a central role in the initiation and direction of immune responses. DC loaded ex vivo with tumour-associated antigens and administered as a vaccine have already shown promise in early clinical trials for a number of lymphoproliferative disorders, but the need for improvement is widely agreed. Recent advances in the understanding of basic DC biology and lessons from early clinical trials have provided exciting new insights into the generation of anti-tumour immune responses and the design of vaccine strategies. In this review we provide an overview of our current understanding of DC biology and their function in patients with lymphoproliferative disorders. We discuss the current status of clinical trials and new approaches to exploit the antigen presenting capacity of DC to design vaccines of the future.

References (288)

  • GallucciS. et al.

    Danger signals: SOS to the immune system

    Curr Opin Immunol

    (2001)
  • MahnkeK. et al.

    Induction of CD4+/CD25+ regulatory T cells by targeting of antigens to immature dendritic cells

    Blood

    (2003)
  • QinZ. et al.

    CD4+ T cell-mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells

    Immunity

    (2000)
  • PardollD.M. et al.

    The role of CD4+ T cell responses in antitumor immunity

    Curr Opin Immunol

    (1998)
  • SmythM.J. et al.

    NKT cells conductors of tumor immunity?

    Curr Opin Immunol

    (2002)
  • PawelecG.

    Immunotherapy and immunoselection-tumour escape as the final hurdle

    FEBS Lett

    (2004)
  • GilboaE.

    The makings of a tumor rejection antigen

    Immunity

    (1999)
  • FuchsE.J. et al.

    Is cancer dangerous to the immune system?

    Semin Immunol

    (1996)
  • WangH.Y. et al.

    Tumor-specific human CD4+ regulatory T cells and their ligands: implications for immunotherapy

    Immunity

    (2004)
  • BombergerC. et al.

    Lymphoid reconstitution after autologous PBSC transplantation with FACS- sorted CD34+ hematopoietic progenitors

    Blood

    (1998)
  • CarboneE. et al.

    HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells

    Blood

    (2005)
  • DhodapkarM.V. et al.

    Antigen-bearing immature dendritic cells induce peptide-specific CD8(+) regulatory T cells in vivo in humans

    Blood

    (2002)
  • Chiriva-InternatiM. et al.

    Sperm protein 17 (Spl 7) is a suitable target for immunotherapy of multiple myeloma

    Blood

    (2002)
  • SinghR.K. et al.

    Immune dysfunction despite high levels of immunoregulatory cytokine gene expression in autologous peripheral blood stem cell transplanted non-Hodgkin lymphoma patients

    Exp Hematol

    (2000)
  • BrownR.D. et al.

    Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor- beta(l) and interleukin-10

    Blood

    (2001)
  • RattaM. et al.

    Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6

    Blood

    (2002)
  • VuckovicS. et al.

    Granulocyte-colony stimulating factor increases CD123hi blood dendritic cells with altered CD62L and CCR7 expression

    Blood

    (2003)
  • FearnleyD.B. et al.

    Monitoring human blood dendritic cell numbers in normal individuals and in stem cell transplantation

    Blood

    (1999)
  • HayashiT. et al.

    Ex vivo induction of multiple myeloma-specific cytotoxic T lymphocytes

    Blood

    (2003)
  • HartD.N. et al.

    Dendritic cell immunotherapy for cancer: application to low-grade lymphoma and multiple myeloma

    Immunol Cell Biol

    (1999)
  • ReichardtV.L. et al.

    DC-based immunotherapy of B-cell malignancies

    Cytotherapy

    (2004)
  • SureshK. et al.

    Recent advances in immunotherapy of B-CLL using ex vivo modified dendritic cells

    Hematology

    (2005)
  • TricotG. et al.

    Predicting long-term (> or =5 years) event-free survival in multiple myeloma patients following planned tandem autotransplants

    Br J Haematol

    (2002)
  • BanchereauJ. et al.

    Dendritic cells and the control of immunity

    Nature

    (1998)
  • ZhangJ. et al.

    Effect of a cancer vaccine prepared by fusions of hepatocarcinoma cells with dendritic cells

    World J Gastroenterol

    (2001)
  • NestleF.O. et al.

    Dendritic cells: On the move from bench to bedside

    Nat Med

    (2001)
  • BanchereauJ. et al.

    Immunobiology of dendritic cells

    Annu Rev Immunol

    (2000)
  • ShortmanK. et al.

    Mouse and human dendritic cell subtypes

    Nat Rev Immunol

    (2002)
  • TrinchieriG.

    Interleukin-12 and the regulation of innate resistance and adaptive immunity

    Nat Rev Immunol

    (2003)
  • EgnerW. et al.

    The phenotype of freshly isolated and cultured human bone marrow allostimulatory cells: possible heterogeneity in bone marrow dendritic cell populations

    Immunology

    (1995)
  • SallustoF. et al.

    Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/ macrophage colony-stimulating factor plus interleukin 4 and down- regulated by tumor necrosis factor alpha

    J Exp Med

    (1994)
  • RomaniN. et al.

    Proliferating dendritic cell progenitors in human blood

    J Exp Med

    (1994)
  • KwakL.W. et al.

    Idiotypic vaccination as therapy for multiple myeloma

    Semin Hematol

    (1999)
  • KatoM. et al.

    Expression of multilectin receptors and comparative FITC-dextran uptake by human dendritic cells

    Int Immunol

    (2000)
  • RandolphG.J. et al.

    The CD16(+) (FcgammaRIII(+)) subset of human monocytes preferentially becomes migratory dendritic cells in a model tissue setting

    J Exp Med

    (2002)
  • TrombettaE.S. et al.

    Cell biology of antigen processing in vitro and in vivo

    Annu Rev Immunol

    (2005)
  • IwasakiA. et al.

    Toll-like receptor control of the adaptive immune responses

    Nat Immunol

    (2004)
  • de Saint-VisB et al.

    The cytokine profile expressed by human dendritic cells is dependent on cell subtype and mode of activation

    J Immunol

    (1998)
  • SmallE.J. et al.

    Immunotherapy of hormone- refractory prostate cancer with antigen-loaded dendritic cells

    J Clin Oncol

    (2000)
  • StollS. et al.

    Production of functional IL-18 by different subtypes of murine and human dendritic cells (DC): DC-derived IL-18 enhances IL-12-dependent Thl development

    Eur J Immunol

    (1998)
  • Cited by (13)

    • Dendritic Cells in Cancer Immunotherapy

      2008, Advances in Cancer Research
      Citation Excerpt :

      In the tissues, MDC include Langerhans cells that are generally found in the epidermis, oral‐respiratory and genital mucosa, and the interstitial DCs present in other tissues. PDC reside mainly in the blood and lymphoid organs (Banchereau and Palucka, 2005; Radford et al., 2005b). Monocyte‐derived DCs (MoDCs) can be generated in vitro by culturing monocytes in the presence of granulocyte/macrophage‐colony stimulating factor (GM‐CSF) and interleukin‐4 (IL‐4) or other cytokines.

    • Enhanced delivery of immunoliposomes to human dendritic cells by targeting the multilectin receptor DEC-205

      2007, Vaccine
      Citation Excerpt :

      During this process, DC migrate into lymph nodes and display the processed antigens to T lymphocytes, thereby eliciting antigen-specific immune responses or tolerance/anergy, depending on the presence or absence of additional costimulatory/tolerogenic signals. Successful delivery of antigens into DC both in vitro and in vivo is a key step for successful vaccination against infectious diseases, cancer and autoimmune diseases [3–5]. A new strategy, which targets DC cell surface proteins, particularly their specialized antigen-loading receptors, has recently been described in mouse models [6–8].

    • Physical activity and hematologic cancer prevention

      2011, Recent Results in Cancer Research
    View all citing articles on Scopus
    View full text